Maha: Minister Gadkari inaugurates Saraswati Karad Hospital in Pune
Pune, June 23 (UNI) Stating that service is the highest virtue and it should be taken to the last person in the society, Union Transport Minister Nitin Gadkar on Monday suggested to increase the graph of happiness of common and poor people in the country.
Addressing the gathering after inauguration of Saraswati Karad Hospital here, he said that the vision of future is very important and in this, along with the government, the society should now work for the society.
The poor people should be served only through service and culture, he said.
The Minister further said that through the Ayushman Yojana, the central government has provided treatment facilities up to Rs five lakh for the poor.
Keeping social sensitivity and awareness, all medical services have been provided to the poor in Nagpur at a very reasonable price, he said.
At a time when the world is struggling due to current turmoil, India has a welfare role to play by giving the message of world peace, Gadkari said and mentioned that world peace should be established on the basis of humanity.
While underscoring the necessity of economic development in the present era, he added that along with resources, spirituality is also important.
UNI SP SS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
an hour ago
- India Today
Wegovy weight-loss drug now in India: How it works and who should take it
Novo Nordisk, a Danish pharmaceutical company, has launched its weight-loss drug Wegovy in India. The drug, which contains semaglutide, works by regulating appetite and food intake, and is now the first medication in India approved for both long-term weight management and heart risk reduction in people who are overweight or WHAT EXACTLY IS WEGOVY, AND HOW DOES IT WORK?At its core, Wegovy is a once-a-week prescription-only injection that mimics a natural hormone in the body called GLP-1 (glucagon-like peptide-1). This hormone plays a key role in appetite regulation. When you take Wegovy, it binds to GLP-1 receptors in the brain, helping to reduce hunger, make you feel full sooner, lowers food cravings and helps control blood sugar biological mechanism makes it easier for people to stick to a lower-calorie diet without constantly feeling deprived—unlike traditional weight-loss methods that rely on sheer willpower THE SCIENCE BEHIND IT? The active ingredient in Wegovy is semaglutide, a compound also used in Novo Nordisk's type 2 diabetes drug Ozempic (not yet available in India). While Ozempic is meant for blood sugar control, Wegovy uses a higher dose of semaglutide (up to 2.4 mg) specifically for weight management and heart health. Wegovy is a once-a-week prescription-only injection that mimics a natural hormonein the body called GLP-1. () Clinical trials have shown that Wegovy, when combined with diet and physical activity, leads to:advertisementUp to 20% body weight reduction in 1 out of 3 people within about 68 weeks20% lower risk of major heart problems such as stroke, heart attack, and death related to cardiovascular disease, especially in people already living with heart conditions and obesityHOW IS WEGOVY TAKEN?Wegovy is administered using an easy-to-use injection pen once a week. It comes in five dosage strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 usually start with the lowest dose and gradually increase to the full dose of 2.4 mg under their doctor's MUCH DOES WEGOVY COST?The first three doses (0.25, 0.5, 1 mg) are priced at Rs 17,345 per month (about Rs 4,366 per week). The 1.7 mg is priced at Rs 24,280 per month and the 2.4 mg (full dose) costs Rs 26,015 for a company says this price structure is designed to make the drug more accessible as obesity cases rise across the THIS MATTERS FOR INDIAIndia has the third highest number of people living with obesity or overweight, according to a major 2023 study by the Indian Council of Medical Research and the Madras Diabetes Research Foundation. The report found that 254 million Indians, or nearly 29% of the population, are affected. The company says this price structure is designed to make the drug more accessible as obesity cases rise across the country. () Obesity is often misunderstood as a lifestyle issue, but experts say it's a chronic condition influenced by genetics, environment, biology, and mental health—not just food or exercise habits. It also increases the risk of over 200 diseases, including type 2 diabetes, heart disease, kidney and liver disorders, and certain SHOULD USE WEGOVY?Wegovy is a prescription-only drug meant for:Adults with a Body Mass Index (BMI) of 30 or higher, orAdults with a BMI of 27 or higher who also have a weight-related health conditionIt must be used under medical supervision, as it can cause side effects in some people, the company stated. "Obesity is not just a personal health concern, it's a national epidemic. Wegovy offers a proven, science-backed solution with the convenience of a user-friendly device. With India-specific pricing and the same cost for the first three doses, we are reinforcing our commitment to address the country's growing obesity burden," said Vikrant Shrotriya, Managing Director of Novo Nordisk like Wegovy and Mounjaro represent a new era in obesity treatment in India, offering hope to millions who struggle with weight and related health issues. By working with the body's natural hunger signals and showing benefits beyond just weight loss, it's more than a slimming aid—it's a chronic care always, people considering Wegovy should consult their doctor to understand whether it's the right fit for their health needs.- EndsMust Watch
New Indian Express
2 hours ago
- New Indian Express
Novo Nordisk rolls out its much-awaited obesity drug Wegovy in India
CHENNAI: Danish drugs and insulin maker Novo Nordisk launched Wegovy, its latest and the much-awaited weight-loss drug -- a once‑a‑week semaglutide injection, in India today (June 24). The drug is currently being distributed and will hit pharmacies by the end of June. The Drug Controller General of India (DCGI) had in February 2025 approved Wegovy for chronic weight management and to reduce cardiovascular events after a select trial. According to the company, the five dose strengths of the obesity drug are available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, and the starter doses (0.25–1 mg) will cost Rs 4,366/week ($50.7), or about ₹17,345/month. While, the higher doses -- 1.7 mg and 2.4 mg are priced at Rs 24,280/month and Rs 26,015/month respectively. According to industry sources, the company advanced the India launch, which was originally planned for 2026, to mid‑2025 to stay ahead of rivals like Eli Lilly's Mounjaro. Novo aims to reach $1 billion in Indian sales within 5–7 years, signaling high confidence in demand, the sources say.
Time of India
2 hours ago
- Time of India
90% of Indians Suffer Dental Issues, but Only 9% Visit Dentists: National Survey
New Delhi: India is facing a silent oral health crisis. New national data shows that 90 per cent of the population suffers from dental problems, yet only nine per cent visit a dentist regularly. A staggering 41 per cent are at high risk for cavities, 44 per cent for gum disease, and 14 per cent for tooth staining — with 72 per cent of Indians at risk for at least one major oral health concern. The country's average oral health score stands at just 2.6 out of 5. As India advances its healthcare ambitions, oral health — long overlooked — is finally being recognised as a crucial part of preventive care. A year-long Oral Health Movement (OHM), conducted in partnership with the Indian Dental Association (IDA), screened more than 4.5 million people across 18,000+ pin codes and over 700 districts — offering one of the most comprehensive pictures of the nation's oral health to date. Union Health Minister JP Nadda and Prabha Narasimhan, MD & CEO of Colgate-Palmolive (India) Limited, presented these findings at the Oral Health Movement Summit 2025 in New Delhi. On the sidelines of the Summit, Prabha Narasimhan spoke to ETHealthworld's Rashmi Mabiyan Kaur about the company's India-specific strategy in the digital FMCG landscape, the future of oral health, how technology and wellness intersect, and why oral care must be seen as preventive health. She also explained how the company is redefining oral care in India — from AI-powered retail precision and science-led product innovation to its mission of creating healthier generations. Q: Oral health is linked to systemic conditions. What role does your company play in India's broader health ecosystem, and which groups should be more sensitised? Yes, oral health is directly linked to systemic conditions like diabetes and cardiovascular diseases. Our role is to amplify awareness of this connection. While we don't comment on the diseases themselves, we emphasise that better oral hygiene leads to better health outcomes. Groups needing greater focus include: Diabetics, who often suffer from gum issues People over 50, who have a higher incidence of gum disease Young children, whose milk teeth determine the health of their permanent teeth It's critical to start early. Good oral habits formed in childhood can last a lifetime. So, we see our role as not just selling toothpaste, but enabling preventive health across age groups. Q: Based on your company's research, what trends are emerging in India's oral healthcare landscape, especially with snacking on the rise? While we don't yet have long-term data, we are seeing clear shifts. One major change is in snacking habits — Indians now eat 4.5 to 5 times a day on average. It's not five meals — it's constant grazing. Each time you eat, your teeth lose calcium. That makes brushing with a high-quality toothpaste more critical than ever. Lifestyle changes mean health habits must evolve. Just as sedentary lifestyles created a need for gyms, modern eating patterns demand better oral hygiene. The old logic of brushing once a day like our grandparents did doesn't work anymore. Q: Is Colgate aligning its portfolio and innovation pipeline with the demand for natural, Ayurvedic oral care products? Consumers buy benefits, not formats. When people choose a toothpaste, they want freshness, whitening, cavity protection, or pain relief — not just 'herbal' or 'natural.' Those are delivery mechanisms, not the end goals. Our focus is to communicate that science-backed products deliver these benefits effectively. No company invests more in oral care R&D than we do, and we bring that technology to consumers in meaningful, perceivable ways. We're committed to addressing the benefit segments — how we get there, whether herbal or otherwise, depends on what delivers the best outcomes. Q: How are you evolving your company's India strategy to ensure sustained leadership in this digitally driven FMCG landscape? We're evolving in several strategic ways to remain ahead in the Indian FMCG space. First, oral health remains at the core of our mission. Within that, our first pillar is to win with our core brands. Driving volume and growth for these brands is essential. The second pillar is premiumisation. The third pillar is driving toothbrush usage. We're market leaders in toothbrushes, but India's average replacement rate is once every nine months — while dentists recommend replacing them every three. We aim to educate and shift consumer behaviour here. Our fourth pillar is diversification, which includes everything beyond oral care. We're growing in the hand wash and body wash segments. We're also evaluating what we can bring in from our global portfolio to strengthen this arm. Q: How are you integrating AI across operations? On the tech front, AI, ML, and digital tools are embedded end-to-end in our operations. We reach 1.7 million stores daily, and what our reps recommend at each store is AI/ML-powered. Even two stores in the same locality may receive completely different product recommendations based on their unique shopper profiles. In manufacturing, most of our factories operate using digital twins, allowing us to monitor processes in real time and ensure top-notch quality. In marketing, we leverage first-party data and cohort targeting, combined with Google's AI suite, to create and adapt content rapidly for specific audiences. It's an exciting time — and we're only scratching the surface of what tech can do for us.
